Home › Obesity › NCT07575399

Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)

RecruitingPhase 3

A Phase 3, Open-label Trial to Evaluate the Efficacy, Safety and Tolerability of Switching From the Glucagon-like Peptide-1 Receptor Agonists to Maridebart Cafraglutide in Adult Participants With Obesity or Overweight

Who can join

Ages 18 to 99 · All sexes

Full eligibility criteria

Inclusion Criteria:

* Body Mass Index (BMI) ≥ 25 at screening.
* Weight loss of ≥ 10% on weekly GLP-1 RA.
* Stable body weight.
* Stable dose of GLP-1RA.
* Stable gastrointestinal (GI) tolerability.
* Contraception for females.
* Willingness to follow trial procedures for the duration of the trial.

Exclusion Criteria:

* Obesity induced by other endocrine disorders (ex: Cushing's syndrome).
* Previous or planned surgical, endoscopic or device-based treatment for obesity.
* History of malignancy.
* Type 1/Type 2 diabetes mellitus (DM).
* Family or personal history of medullary thyroid cancer.
* Previous participation in a Maridebart Cafraglutide trial.

About the study

Efficacy, safety and tolerability of switching from GLP-1RA to maridebart cafraglutide in adults with obesity or overweight.

What is being tested

Maridebart Cafraglutide (drug)

Sponsor: Amgen · Participants: 300 · Started: May 11, 2026

Contact the study team

Amgen Call Center · Phone: 866-572-6436

Official record on ClinicalTrials.gov — NCT07575399

Locations in the U.S.

Alabama	Cahaba Research, Inc., Pelham
Arizona	Arizona Clinical Trials, Chandler Epic Medical Research - Sun City, Sun City
California	Desert Oasis Healthcare Medical Group, Palm Springs Inland Empire Liver Foundation, Rialto Peninsula Research Associates, Rolling Hills Estates Apex Clinical Research, San Diego Southern California Clinical Research, Santa Ana
Florida	University of Florida Department of Medicine, Gainesville Aga Clinical Trials, Hialeah South Florida Clinical Research, Margate New Horizon Research Center, Miami Research Institute of South Florida, Miami Clinical Neuroscience Solutions, Orlando Florida Institute for Clinical Research, Orlando Progressive Medical Research, Port Orange Charter Research - The Villages, The Villages
Georgia	Nsc Research, Johns Creek Rophe Adult and Pediatric Medicine/Sky Clinical Research Network Group, Union City North Georgia Clinical Research, Woodstock
Idaho	Solaris Clinical Research, Meridian
Illinois	Endeavor Health, Skokie
Louisiana	Pennington Biomedical Research Center, Baton Rouge
Michigan	Arcturus Healthcare, Public Limited Company, Troy Internal Medicine Research Division, Troy
Mississippi	Sky Integrative Medical Center, Ridgeland
Montana	Montana Medical Research, Missoula
Nevada	Excel Clinical Research, Las Vegas
New York	Icahn School of Medicine at Mount Sinai, New York Rochester Clinical Research, Rochester
North Carolina	Centricity Research Morehead City Specialty, Morehead City Accellacare of Raleigh, Raleigh Accellacare Research of Wilmington, Wilmington
Oklahoma	Epic Medical Research - Oklahoma, Chickasha Lynn Health Science Institute, Oklahoma City
Pennsylvania	Altoona Center for Clinical Research, Duncansville
Texas	Epic Medical Research - DeSoto, DeSoto South Texas Research Institute, Edinburg Biopharma Informatic, LLC, Houston Research Physicians Network, LLC, Houston Texas Institute of Cardiology, McKinney North Hills Medical Research, North Richland Hills VIP Trials, San Antonio Northwest Houston Heart Center, Tomball
Washington	Eastside Research Associates Health Research, Redmond

Conditions

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.